Last week, Cantor's Capital Introduction team hosted its inaugural Biotech Panel, moderated by Senior Managing Director and Senior Biotechnology Analyst, Eric Schmidt, Ph.D. Panelists shared their insights on the latest trends and future directions in biotechnology, discussing groundbreaking therapies, diagnostics, and innovative solutions driving the sector forward. A special thank you to our panelists for their invaluable contributions to the success of this event: Anna Cosslett Yaeger, Partner & Head of Public Equities of 5AM Ventures; Vincent Aita, CIO & Managing Partner of Cutter Capital Management, LP; Kevin Pyun, CIO of Dellora Investments; and Rod Wong, CIO & Managing Partner of RTW Investments, LP. If you missed the panel or are interested in learning more about Cantor Prime Services and our Capital Introduction capabilities, please reach out to us here: https://lnkd.in/eB6TnVmE.
Cantor Fitzgerald’s Post
More Relevant Posts
-
Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF
To view or add a comment, sign in
-
Are you attending RESI Boston next week? If so, join Portal and Radyus Research for a panel discussion with our Director of Lab and Scientific Operations, Krisha Panchalingam! This panel will discuss maximizing pre-clinical development success for VC-backed startups through CRO partnerships. Additional information is below, and we hope to see you there!
Join us at RESI Boston next week presented by Life Science Nation! Radyus Research CEO and co-founder, Dr. Marta New will be moderating a panel on September 18th at 3pm ET featuring Sean Evans Senior Associate, Venture Investments of Johnson & Johnson, Carrie Saulsbery CSO of IGM Biosciences, Inc., Roman Fleck Executive Chairman of HDAX Therapeutics, and Krisha Panchalingam Director of Lab and Scientific Operations of Portal Innovations, LLC. You can also stop by and see us at exhibition table 3. #RESIBOS #Biotech #RESIBOSTON #preclinicalresearch #preclinical #vcfunding
To view or add a comment, sign in
-
-
🏥 Akiram Therapeutics: The transition from lab to market We are happy to see Akiram Therapeutics, one of our portfolio companies, featured in Life Science Sweden. The article explores the significant journey undertaken by Marika Nestor, CEO at Akiram, along with her team, who navigated the path from academia at Uppsala University to an established biotech company. This transition, which involved translating research into a viable commercial entity, underscores the challenges and triumphs of moving from lab bench to patient bedside. With Akiram, we see the critical steps of securing funding and navigating patent landscapes to produce novel treatments for clinical trials. Find the full feature (in Swedish) here: https://lnkd.in/dYtCZqtw At Sciety, this is what we do. We invest in life science and health tech companies like Akiram, that have the potential to make a real difference in people's lives. We are a long-term partner supporting the growth of our portfolio companies, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. Want to learn more about how we work and what we invest in? Visit our website: https://lnkd.in/dQMctGqm #Sciety #VentureCapital #LifeScience
To view or add a comment, sign in
-
-
Uncover the Secrets of Biotech IT Evolution: Dive into the 'Calculus of IT' with Nathan McBride of Xilio Therapeutics, Inc. As the biotech industry surges forward, it is imperative to grasp the fundamental elements that define success. From do's and don'ts that can make or break a biotech's journey to finely-tuned launchpad strategies tailored for emerging players in the field, Nate delves into it all in our on-demand video. Watch the whole video here: bit.ly/44oJkq8 For more videos from our Life Sciences Summit, visit: bit.ly/3QwcFeU #LifeSciences #Biotech #ClinicalTrials
Egnyte Life Sciences Summit: The Calculus of IT
To view or add a comment, sign in
-
Not long after the official divestment of GRAIL, Illumina have now officially acquired single cell multi-omics player Fluent BioSciences Inc.! We feel Illumina are telegraphing their intentions to increase dominance within the growing single cell multi-omics sector, which is poised to hit a market value of$𝟯𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟯 👀📈 We wish both Illumina & Fluent BioSciences Inc. the utmost success 🫱🏽🫲🏼 #acquistion #multiomics #masonhardingnews
To view or add a comment, sign in
-
-
With registration in full swing, we want to take a moment to highlight our case company and key sponsors! We will be showcasing each company throughout the registration period, so follow to learn more about these amazing organizations. As a reminder, case teams must complete an application here by Nov. 27 to register! Application here: https://lnkd.in/eyv49w3d Today, we are highlighting our case company, Orange Grove Bio ! Orange Grove Bio’s mission is to positively transform the quality of life of patients with cancer, autoimmune, and inflammatory diseases, by expediting the development of new medical breakthroughs. They strive to foster a more patient-centric approach to drug development and curative therapies through a collaborative ecosystem that bridges early-stage research and pharmaceutical companies. Orange Grove Bio’s Chief Executive Officer and Co-Founder, Marc Appel was an entrepreneur-in-residence at Yale University. In this role, Marc drove the initiative that propelled university intellectual property into the hands of startups to further fuel the New Haven innovation ecosystem. Orange Grove Bio focuses on geographies outside prime venture capital hubs, including the Southeast, Midwest, and Mid-Atlantic. Sourcing throughout these regions aids in accelerating drug development of valuable therapeutics that receive billions of dollars in annual NIH funding, which are more distant from traditional venture capital regions. #innovation #biotech #YHSI2024 #casecompetition
To view or add a comment, sign in
-
-
🔍 Discover the leading figures in the Biotech investment world! Meet the top investors who are fueling the future of healthcare with innovation and insight. 🌟 Peter Kolchinsky 🌐 Location: Boston, Massachusetts 💼 Company: RA Capital Management 🔬 Focus: Healthcare, Medical Device, Health & Wellness, BioTech, Life Science, Pharmaceuticals, AI & ML 🚀 Stage: Pre-Seed to Series D 📈 # of Investments: 288 🌱 Notable Portfolio: Somatus, Exo, Element Biosciences, and many more! 🌟 David Rossow 🌐 Location: New York 💼 Company: Bill & Melinda Gates Foundation 🔬 Focus: BioTech, Professional Services, Medical Device, AgTech, and more 🚀 Stage: Seed to Series D 📈 # of Investments: 199 🌱 Notable Portfolio: Vedanta Biosciences, Inc., Provivi, Inc., BetterLesson, AgBiome 🌟 Stéphane BERGEZ 🌐 Location: Paris, France 💼 Company: Andera Partners 🔬 Focus: BioTech, Medical Device, Pharmaceuticals 🚀 Stage: Seed to Series D 📈 # of Investments: 173 🌱 Notable Portfolio: Mineralys Therapeutics, Inc. 🌟 Cory Freedland 🌐 Location: Palo Alto, California 💼 Company: Samsara BioCapital 🔬 Focus: BioTech, Medical Device, Pharmaceuticals, Healthcare, Life Science 🚀 Stage: Pre-Seed to Series D 📈 # of Investments: 91 🌱 Notable Portfolio: Mineralys Therapeutics, Inc., Alamar Biosciences, Inc., Abata Therapeutics 🌟 Dayton Misfeldt 🌐 Location: Menlo Park, California 💼 Company: Decheng Capital 🔬 Focus: BioTech, Healthcare, Life Science, Big Data & Analytics 🚀 Stage: Seed 📈 # of Investments: 71 🌱 Notable Portfolio: GenapSys, ACELYRIN, INC., LevitasBio 🔗 For the full list of top biotech angel investors: https://lnkd.in/dRDVFW4C #Biotech #HealthcareInnovation #Investment #VentureCapital #LifeSciences #MedicalDevices #Pharmaceuticals #TechInvestors #AngelInvestors #FolkApp
Biotech angel investors
folk.app
To view or add a comment, sign in
-
Given the current trajectory of the biotech sector, how prepared are you to ensure the continuity and integrity of your CMC development plan? Remember, it's a critical link in the value chain—can you afford to let it lapse? Reach out for a consultation and be sure to remain on track.
"The unprecedented surge in biotech M&A activity this early October is reshaping the industry landscape. With such a torrid pace, one has to wonder: Are we witnessing the dawn of a new era or just a fleeting moment in the biotech sector's evolution?"
Early October Sees Torrid Pace of Biotech M&A—Will It Continue? | BioSpace
biospace.com
To view or add a comment, sign in
-
Did you miss our Q4 Earnings Call? Do you want to hear about our increasing sales, an update on the US sales, the newest commercial agreements, and growth in our Pharma Portfolio? Due to time constraints we did not manage to address all questions we received during the meeting, but you will find it in writing with the recording. Watch the recording and read the Q&A document here: https://loom.ly/ADFKOcg Presenters: Anders Rylander, CEO Anders Morén, CFO Henrik Winther, SVP Business Development Hector Tamburini, Head of US Operations #biovicb #investors #oncology #nasdaqfirstnorth
To view or add a comment, sign in
-
-
#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉 The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community. We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape. See you there! ✍ Find the registration link in the first comment.
To view or add a comment, sign in
-